Evidence-based clinical practice guidelines for Liver Cirrhosis 2020
- PMID: 34231046
- PMCID: PMC8280040
- DOI: 10.1007/s00535-021-01788-x
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020
Abstract
The first edition of the clinical practice guidelines for liver cirrhosis was published in 2010, and the second edition was published in 2015 by the Japanese Society of Gastroenterology (JSGE). The revised third edition was recently published in 2020. This version has become a joint guideline by the JSGE and the Japan Society of Hepatology (JSH). In addition to the clinical questions (CQs), background questions (BQs) are new items for basic clinical knowledge, and future research questions (FRQs) are newly added clinically important items. Concerning the clinical treatment of liver cirrhosis, new findings have been reported over the past 5 years since the second edition. In this revision, we decided to match the international standards as much as possible by referring to the latest international guidelines. Newly developed agents for various complications have also made great progress. In comparison with the latest global guidelines, such as the European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases (AASLD), we are introducing data based on the evidence for clinical practice in Japan. The flowchart for nutrition therapy was reviewed to be useful for daily medical care by referring to overseas guidelines. We also explain several clinically important items that have recently received focus and were not mentioned in the last editions. This digest version describes the issues related to the management of liver cirrhosis and several complications in clinical practice. The content begins with a diagnostic algorithm, the revised flowchart for nutritional therapy, and refracted ascites, which are of great importance to patients with cirrhosis. In addition to the updated antiviral therapy for hepatitis B and C liver cirrhosis, the latest treatments for non-viral cirrhosis, such as alcoholic steatohepatitis/non-alcoholic steatohepatitis (ASH/NASH) and autoimmune-related cirrhosis, are also described. It also covers the latest evidence regarding the diagnosis and treatment of liver cirrhosis complications, namely gastrointestinal bleeding, ascites, hepatorenal syndrome and acute kidney injury, hepatic encephalopathy, portal thrombus, sarcopenia, muscle cramp, thrombocytopenia, pruritus, hepatopulmonary syndrome, portopulmonary hypertension, and vitamin D deficiency, including BQ, CQ and FRQ. Finally, this guideline covers prognosis prediction and liver transplantation, especially focusing on several new findings since the last version. Since this revision is a joint guideline by both societies, the same content is published simultaneously in the official English journal of JSGE and JSH.
Keywords: Complications; Diagnosis; Guidelines; Liver cirrhosis; Treatment.
© 2021. The Author(s).
Conflict of interest statement
Any financial relationship with enterprises, businesses or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows: (1) those from which the enterprises and for-profit organizations received remuneration paid as patent royalties; SRL, (2) those from which the authors, the spouse, partner or immediate relatives of the authors have received individually any income, honoraria or any other type of renumeration; Abbvie, Otsuka Pharmaceutical, Gilead Sciences, Sumitomo Dainippon Pharma, MSD, Eisai, EA Pharma, Bristol Myers Squibb, Mitsubishi Tanabe Pharma, Bayer Yakuhin, ASKA Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical, Taiho Pharmaceutical, Chugai Pharmaceutical, (3) those from which the academic institutions of the authors received support (commercial/academic cooperation); Abbvie, Otsuka Pharmaceutical, EA Pharma, Gilead Sciences, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Bristol Myers Squibb, Eisai, MSD, Nippon Kayaku, Ono Pharmaceutical, Teijin Pharma, Novartis Pharma, ASKA Pharmaceutical, Astellas Pharmaceutical, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Toray, Mochida Pharmaceutical, Interstem, Rohto Pharmaceutical, Towa Pharmaceutical, Nihon Pharmaceutical, Janssen Pharmaceutical, MIC Medical, Kowa, and 4)those from which the authors have received individually endowed chair;Shibuya Corporation.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8280040/bin/535_2021_1788_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8280040/bin/535_2021_1788_Fig2_HTML.gif)
![Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8280040/bin/535_2021_1788_Fig3_HTML.gif)
![Fig. 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8280040/bin/535_2021_1788_Fig4_HTML.gif)
Similar articles
-
Evidence-based clinical practice guidelines for cholelithiasis 2021.J Gastroenterol. 2023 Sep;58(9):801-833. doi: 10.1007/s00535-023-02014-6. Epub 2023 Jul 15. J Gastroenterol. 2023. PMID: 37452855 Free PMC article. Review.
-
Usefulness of nutritional therapy recommended in the Japanese Society of Gastroenterology/Japan Society of Hepatology evidence-based clinical practice guidelines for liver cirrhosis 2020.J Gastroenterol. 2021 Oct;56(10):928-937. doi: 10.1007/s00535-021-01821-z. Epub 2021 Sep 17. J Gastroenterol. 2021. PMID: 34533633
-
Evidence-based clinical practice guidelines for liver cirrhosis 2020.Hepatol Res. 2021 Jul;51(7):725-749. doi: 10.1111/hepr.13678. Epub 2021 Jul 6. Hepatol Res. 2021. PMID: 34228859
-
Evidence-based clinical practice guidelines for management of colorectal polyps.J Gastroenterol. 2021 Apr;56(4):323-335. doi: 10.1007/s00535-021-01776-1. Epub 2021 Mar 12. J Gastroenterol. 2021. PMID: 33710392 Free PMC article. Review.
-
Evidence-based clinical practice guidelines for liver cirrhosis 2015.J Gastroenterol. 2016 Jul;51(7):629-50. doi: 10.1007/s00535-016-1216-y. Epub 2016 May 31. J Gastroenterol. 2016. PMID: 27246107 Review.
Cited by
-
Navigating the controversy regarding antibiotic prophylaxis in acute variceal bleeding.World J Gastroenterol. 2024 May 14;30(18):2485-2487. doi: 10.3748/wjg.v30.i18.2485. World J Gastroenterol. 2024. PMID: 38764763 Free PMC article.
-
MRI radiomics based on deep learning automated segmentation to predict early recurrence of hepatocellular carcinoma.Insights Imaging. 2024 May 20;15(1):120. doi: 10.1186/s13244-024-01679-8. Insights Imaging. 2024. PMID: 38763975 Free PMC article.
-
Design and development of a self-care application for patients with liver cirrhosis.Gastroenterol Hepatol Bed Bench. 2024;17(1):74-86. doi: 10.22037/ghfbb.v17i1.2846. Gastroenterol Hepatol Bed Bench. 2024. PMID: 38737927 Free PMC article.
-
Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis.Sci Rep. 2024 May 11;14(1):10784. doi: 10.1038/s41598-024-60235-y. Sci Rep. 2024. PMID: 38734732 Free PMC article.
-
ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.J Gastroenterol. 2024 May 10. doi: 10.1007/s00535-024-02109-8. Online ahead of print. J Gastroenterol. 2024. PMID: 38727822
References
-
- Higgins JPT, Thomas J, Chandler J. Cochrane Handbook for Systematic Reviews of Interventions version 6.0. https://training.cochrane.org/handbook/current. 2019.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous